Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
Prelude Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.